Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03289780|
Recruitment Status : Recruiting
First Posted : September 21, 2017
Last Update Posted : September 25, 2017
|Condition or disease|
|Non-Small Cell Lung Cancer|
The primary purpose of this observational study is to assess the physician's clinical practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR mutational status. This study will also attempt to further validate that VeriStrat test results stratify subjects by clinical outcomes in the real world, uncontrolled clinical setting while exploring whether certain therapeutic approaches may yield opportunities for further study.
Predictive tests that aid physician therapeutic decision making are critical for optimizing subject outcomes while minimizing toxicity and associated treatment costs. This study will provide data for the validation of immunotherapy tests currently being developed. Immunotherapy mechanisms are dependent upon the interactions between the tumor, tumor microenvironment, and the patient immune system. As such, a successful predictive test will reflect the complex interplay between tumor and host. The multivariate tests from Biodesix have the advantage of being able to assess this complex biology.
The information gained from this research will not only guide the adoption of the VeriStrat test and inform medical decision making, including treatment choice, but will allow the validation of additional mass-spectrometry-based proteomic tests.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer|
|Actual Study Start Date :||April 4, 2016|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 2020|
- Physician Treatment Patterns Description [ Time Frame: 18 months ]1. Physician Treatment patterns Description: To describe physician treatment patterns pre and post-veriStrat testing. Describe the impact of the VeriStrat test results on treatment decisions, including but not limited to: percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat good and those classified as VeriStrat Poor. Change in percentage of patients receiving systemic therapy or supportive therapies only.
- Immunotherapy Stratification by Overall Survival [ Time Frame: 18 month ]To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by overall survival.
- Immunotherapy Stratification by Progression-Free Survival [ Time Frame: 18 months ]To determine whether immunotherapy test(s) stratify immunotherapy-treated subjects by progression-free survival.
- VeriStrat Poor vs. Good Outcomes [ Time Frame: 18 months ]To compare progression free survival (PFS) and overall survival (OS) outcomes between those classified as VeriStrat-Poor and VeriStrat-Good.
- Platinum-based therapy outcomes in VeriStrat Poor vs. Good subjects. [ Time Frame: 18 months ]To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with platinum-based therapy.
- Immunotherapy outcomes in VeriStrat Poor vs. Good subjects. [ Time Frame: 18 months ]To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with immunotherapy.
- Gemcitabine outcomes in VeriStrat Poor vs. Good Subjects [ Time Frame: 18 months ]To compare outcomes in subjects classified as VeriStrat-Poor and VeriStrat-Good and treated with gemcitabine.
- VeriStrat label changes over time. [ Time Frame: 18 months ]To compare the longitudinal changes in VeriStrat classification over the course of the study
- Determination of Immunotherapy tests ability to stratify subjects based on treatment. [ Time Frame: 18 months ]To compare progression free survival (PFS) and overall survival (OS) outcomes in patients as stratified by the immunotherapy test(s) treated with chemotherapy or targeted therapies.
- Correlation between the VeriStrat test and Immunotherapy tests. [ Time Frame: 18 months ]To observe the correlation between VeriStrat classification and immunotherapy test(s) classification at baseline and longitudinally.
- Longitudinal changes in Immunotherapy tests. [ Time Frame: 18 months ]To describe the longitudinal changes in immunotherapy test classification over the course of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03289780
|Contact: Niki Givens, B.S.||firstname.lastname@example.org|
|Contact: Alix Arnaud, M.Semail@example.com|
|Principal Investigator:||Linda Traylor, Ph.D||Biodesix, Inc.|